These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 4054341)

  • 1. Bioavailability of oral micronized progesterone.
    Maxson WS; Hargrove JT
    Fertil Steril; 1985 Nov; 44(5):622-6. PubMed ID: 4054341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
    Carr BR; Parker CR; Madden JD; MacDonald PC; Porter JC
    J Clin Endocrinol Metab; 1979 Sep; 49(3):346-9. PubMed ID: 224073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration.
    Ottoson UB; Carlstrom K; Damber JE; von Schoultz B
    Br J Obstet Gynaecol; 1984 Nov; 91(11):1111-9. PubMed ID: 6498126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative bioavailability of orally and vaginally administered progesterone.
    Norman TR; Morse CA; Dennerstein L
    Fertil Steril; 1991 Dec; 56(6):1034-9. PubMed ID: 1743318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Contraception with pure, synthetic progestogens of the norpregnane group, a new approach for the future?].
    Rozenbaum H
    Contracept Fertil Sex (Paris); 1986 Jun; 14(6):577-81. PubMed ID: 12341096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of nasally administered progesterone.
    Steege JF; Rupp SL; Stout AL; Bernhisel M
    Fertil Steril; 1986 Oct; 46(4):727-9. PubMed ID: 3758397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LH, FSH, estradiol and progesterone levels after discontinuation of hormonal contraception.
    Balogh A; Ditrói F; Lampé LG
    Acta Univ Palacki Olomuc Fac Med; 1981; 101():95-101. PubMed ID: 6242699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of estrogen and progesterone on the functional capacity of the gonadotrophs.
    Lasley BL; Wang CF; Yen SS
    J Clin Endocrinol Metab; 1975 Nov; 41(5):820-6. PubMed ID: 1102551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The circadian pattern of melatonin and its positive relationship with progesterone in women.
    Webley GE; Leidenberger F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):323-8. PubMed ID: 3722324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal relationships between ovulation and defined changes in the concentration of plasma estradiol-17 beta, luteinizing hormone, follicle-stimulating hormone, and progesterone. I. Probit analysis. World Health Organization, Task Force on Methods for the Determination of the Fertile Period, Special Programme of Research, Development and Research Training in Human Reproduction.
    Am J Obstet Gynecol; 1980 Oct; 138(4):383-90. PubMed ID: 6775535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ultrasonic and hormonal monitoring of the ovaries during mini-dose oral contraception].
    Doyen J; Schaaps JP; Lambotte R
    Contracept Fertil Sex (Paris); 1987 May; 15(5):529-33. PubMed ID: 12268693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the effects of oestradiol, progesterone and some steroidal contraceptives on the adrenal cortex of albino rats.
    Zaki K; Sami GE; Wassef SA; Nour H; Hassan AA
    Egypt Popul Fam Plann Rev; 1973 Jun; 6(1):33-50. PubMed ID: 12257875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal and menstrual changes after laparoscopic sterilization by Falope-rings or Filshie-clips.
    Thranov I; Hertz JB; Kjer JJ; Andresen A; Micic S; Nielsen J; Hancke S
    Fertil Steril; 1992 Apr; 57(4):751-5. PubMed ID: 1532561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
    Lemay A; Dewailly SD; Grenier R; Huard J
    J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.